KROS
Keros Therapeutics Inc

1,284
Loading...
Loading...
News
all
press releases
Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of +33.33% and +135.95%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
More News
News Placeholder
KROS vs. EXAS: Which Stock Should Value Investors Buy Now?
KROS vs. EXAS: Which Stock Is the Better Value Option?
Zacks·1mo ago
News Placeholder
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
Zacks·2mo ago
News Placeholder
RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data.
Zacks·2mo ago
News Placeholder
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
Zacks·2mo ago
News Placeholder
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
Zacks·2mo ago
News Placeholder
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
Rhythm Pharmaceuticals jumps 36.6% after its oral drug bivamelagon shows strong BMI and hunger reductions in a phase II study in acquired hypothalamic obesity.
Zacks·2mo ago
News Placeholder
Keros Therapeutics Adopts Defense Strategy Against Potential Hostile Takeover, Explores Sale: Retail’s Overjoyed
The company said the plan aims to reduce the likelihood of any entity or person gaining control of Keros through open-market accumulation without paying all stockholders an appropriate control premium.
Stocktwits·5mo ago
News Placeholder
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros...
PR Newswire·7mo ago
News Placeholder
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·7mo ago

Latest KROS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.